ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

How NCI Would Apportion New Round Of budget Cuts- 1980 $17 Million, 1981 $42.7 Million

April 11, 1980

Organ Systems Program Adds Workshops On Lung, Colorectal Cancer

January 26, 1990

Soybean Studies, Computing Support Recompetition Ok’d

November 9, 1990

In Brief: Kennedy To Stay On Health Committee; Animal Research Bills Probably Dead For This Congress

December 10, 1982

Eugenia Calle, 57, ACS Epidemiologist, Found Dead at Home; Murder Suspect Arrested

February 20, 2009

Study Identifies Women Likely To Benefit From Therapy With Aromatase Inhibitors

November 24, 2006